Cargando…

Effects of NO/cGMP inhibitors in a rat model of anaphylactoid shock

Anaphylactic shock can be defined as an acute syndrome, and it is the most severe clinical manifestation of allergic diseases. Anaphylactoid reactions are similar to anaphylactic events but differ in the pathophysiological mechanism. Nitric oxide (NO) inhibitors during anaphylaxis suggest that NO mi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albuquerque, A.A.S., Ferreira, L.G., Carvalho, M.T.M., Capellini, V.K., Evora, P.R.B., Celotto, A.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Divulgação Científica 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057939/ https://www.ncbi.nlm.nih.gov/pubmed/32130289 http://dx.doi.org/10.1590/1414-431X20198853

Ejemplares similares

Acute but not chronic metabolic acidosis potentiates the acetylcholine-induced reduction in blood pressure: an endothelium-dependent effect
por: Celotto, A.C., et al.
Publicado: (2015)

G-Proteins Agonists and NO/cGMP Blockers: Unexplored Frontiers in the Pharmaceutical Industry
por: Evora, Paulo Roberto B.
Publicado: (2017)

Why Methylene Blue Is the Only Option for Blocking the cGMP/NO Pathway in The Treatment of Vasoplegic Shock? “Reasons That Reason Itself Does Not Know...”
por: Evora, Paulo Roberto B., et al.
Publicado: (2021)

Blocking soluble guanylate cyclase could be the present and future of NO/cGMP inhibition for vasoplegia treatment
por: Barbosa Evora, Paulo Roberto
Publicado: (2018)

NO/cGMP signalling in platelets
por: Schinner, Elisabeth, et al.
Publicado: (2009)

cGMP and cardiac hypertrophy
por: Perera, Ruwan K, et al.
Publicado: (2015)

Elevated retinal cGMP is not associated with elevated circulating cGMP levels in a canine model of retinitis pigmentosa
por: Occelli, Laurence M., et al.
Publicado: (2022)

Analysis of cGMP signalling with transgenic mice expressing FRET-based cGMP sensors
por: Wen, Lai, et al.
Publicado: (2013)

The role of cGMP and PKG in cardioprotection
por: Downey, James M, et al.
Publicado: (2009)

Anaphylactoid Edema
por: Levine, Robert J.
Publicado: (1969)

cGMP-Dependent Protein Kinase Inhibitors in Health and Disease
por: Wolfertstetter, Stefanie, et al.
Publicado: (2013)

Transient kinetics of a cGMP-dependent cGMP-specific phosphodiesterase from Dictyostelium discoideum
Publicado: (1984)

Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling
por: Mullershausen, Florian, et al.
Publicado: (2003)

PDE5 says NO to cGMP
por: LeBrasseur, Nicole
Publicado: (2003)

cGMP steers axons home
por: LeBrasseur, Nicole
Publicado: (2002)

A novel pathway of cGMP
por: Kuhn, Michaela, et al.
Publicado: (2011)

NO-cGMP signalling and cancer therapy
por: Bian, Ka, et al.
Publicado: (2013)

Role of cGMP in fat and metabolism
por: Pfeifer, Alexander, et al.
Publicado: (2013)

cGMP Signaling in Photoreceptor Degeneration
por: Li, Shujuan, et al.
Publicado: (2023)

Inhibition of the TGFβ signalling pathway by cGMP and cGMP‐dependent kinase I in renal fibrosis
por: Schinner, Elisabeth, et al.
Publicado: (2017)

cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development
por: Friebe, Andreas, et al.
Publicado: (2019)

Metabolic fate of orally administered cGMP in rats
por: Liong, Elaine, et al.
Publicado: (2013)

Forty-five years of cGMP research in Dictyostelium: understanding the regulation and function of the cGMP pathway for cell movement and chemotaxis
por: van Haastert, Peter J. M., et al.
Publicado: (2021)

The 10th International Conference on cGMP 2022: recent trends in cGMP research and development—meeting report
por: Friebe, Andreas, et al.
Publicado: (2023)

Structural and mechanistic insights into cGMP signaling
por: Rauch, Annika, et al.
Publicado: (2009)

Vascular and renal function of cGMP signalling
por: Schlossmann, Jens, et al.
Publicado: (2011)

Role of cGMP/PKG in fat tissue
por: Pfeifer, Alexander
Publicado: (2011)

cGMP becomes a drug target
por: Schlossmann, Jens, et al.
Publicado: (2012)

NO-H(2)S interactions involve cGMP
por: Papapetropoulos, Andreas
Publicado: (2013)

cGMP kinase: past, presence and future
por: Hofmann, Franz, et al.
Publicado: (2013)

Natriuretic peptides and cGMP in metabolic disease
por: Collins, Sheila
Publicado: (2015)

NO-dependent cGMP signalling in neurons and astrocytes
por: Giesen, Jan, et al.
Publicado: (2015)

Modulating cGMP to Treat Lung Diseases
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2009)

Natriuretic Peptides/cGMP/cGMP-Dependent Protein Kinase Cascades Promote Muscle Mitochondrial Biogenesis and Prevent Obesity
por: Miyashita, Kazutoshi, et al.
Publicado: (2009)

L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway.
por: Duarte, I D, et al.
Publicado: (2000)

Acute stress-induced antinociception is cGMP-dependent but heme oxygenase-independent
por: Carvalho-Costa, P.G., et al.
Publicado: (2014)

Acute exercise inhibits gastric emptying of liquids in rats: influence of the NO-cGMP pathway
por: Cavalcante, A.K.M., et al.
Publicado: (2018)

Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux
por: Subbotina, Anna, et al.
Publicado: (2017)

The ANP/cGMP/cGMP-dependent protein kinase pathway counteracts Angiotensin II-stimulated calcium mobilization in cardiac myocytes
por: Klaiber, Michael, et al.
Publicado: (2009)

Extracellular cGMP Modulates Learning Biphasically by Modulating Glycine Receptors, CaMKII and Glutamate-Nitric Oxide-cGMP Pathway
por: Cabrera-Pastor, Andrea, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9octhnj4o53nielinifnh3vilj